Search

Your search keyword '"Hindley R"' showing total 223 results
Start Over Author "Hindley R"
223 results on '"Hindley R"'

2. Focal HIFU and cryotherapy for prostate cancer: A HEAT and ICE analysis of 15-year usage trends in the United Kingdom

Author

Light, A., primary, Mayor, N., additional, Cullen, E., additional, Arya, M., additional, Grey, A., additional, Orczyk, C., additional, Moore, C.M., additional, Emberton, M., additional, Dudderidge, T., additional, Hindley, R., additional, Emara, A., additional, Noureldin, M., additional, Nigam, R., additional, Virdi, J., additional, Laniado, M., additional, Mccraken, S., additional, Greene, D., additional, Ahmed, H.U., additional, and Shah, T.T., additional

Published
2024
Full Text
View/download PDF

3. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project

Author

van Luijtelaar, A., Greenwood, B. M., Ahmed, H. U., Barqawi, A. B., Barret, E., Bomers, J. G. R., Brausi, M. A., Choyke, P. L., Cooperberg, M. R., Eggener, S., Feller, J. F., Frauscher, F., George, A. K., Hindley, R. G., Jenniskens, S. F. M., Klotz, L., Kovacs, G., Lindner, U., Loeb, S., Margolis, D. J., Marks, L. S., May, S., Mcclure, T. D., Montironi, R., Nour, S. G., Oto, A., Polascik, T. J., Rastinehad, A. R., De Reyke, T. M., Reijnen, J. S., de la Rosette, J. J. M. C. H., Sedelaar, J. P. M., Sperling, D. S., Walser, E. M., Ward, J. F., Villers, A., Ghai, S., and Fütterer, J. J.

Published
2019
Full Text
View/download PDF

6. Who is at risk of death from nephrectomy? An analysis of thirty‐day mortality after 21 380 nephrectomies in 3 years of the British Association of Urological Surgeons (BAUS) National Nephrectomy Audit

Author

Fernando, Archie, Fowler, Sarah, Van Hemelrijck, Mieke, OʼBrien, Tim, Abbasi, Z., Adamson, A. S., Addla, S. K., Adeyoju, A. A., Adshead, J. M., Afzal, N., Aho, T. F., Akhtar, M., Al‐Akraa, M., Al‐Sudani, M., Alam, A., Allan, J., Almond, D. J., Anderson, C. J., Andrews, S. J., Apakama, I., Armitage, T., Armitage, J., Awsare, N., Ayres, B., Banerjee, G. K., Barber, N. J., Barua, J. M., Basu, S., Bdesha, A. S., Beacock, C. J. M., Beatty, J., O Beck, R., Belal, M., Bell, C. R. W., Bhanot, S. M., Bhatt, R., Bhatti, A., Biyani, C. S., Blacker, A. J., Blades, R. A., Blake, C., Blake‐James, B., Boddy, J., Bromage, S. J., Bromwich, E., Brown, C., Browning, A. J., Bryan, N. P., Burgess, N. A., Burns‐Cox, N., Butterworth, P. C., Bycroft, J., Calleary, J. G., Calvert, R. C., Campbell, I., Campbell, C. A., Cannon, A., Carter, P. G., Carter, C. J. M., Cartledge, J. J., Casey, R., Chakravarti, A., Challacombe, B., Chandrasekharan, S., Chappell, B. G., Chaudry, A., Chen, T. F., Cherian, J., Choi, W. H., Chow, K., Clavijo Eisele, J., Cliff, A. M., Cohen, N. P., Cole, O. J., Collins, J., Connolly, S., Cooke, P. W., Cooksey, G., Cornaby, A. J., Cornford, P. A., Corr, J. G., Coulthard, R., Cranston, D. W., Cresswell, J., Crundwell, M. C., Cutinha, P. E., Cynk, M., Daruwala, P. D., Dasgupta, P., Datta, S. N., Davenport, K., de Bolla, A. R., Devarajan, R., Dickerson, D. A. G., Dickinson, A. J., Doherty, A. P., Donaldson, P. J., Dudderidge, T., Dyer, J., Eaton, J., Eddy, B., Eden, C. G., Elsaghir, M., Evans, S. D., Fiala, R., Fordham, M. V. P., Foster, M. C., French, A. J., Frymann, R. J., Gall, Z. J., Gallegos, C. R. R., Gana, H. B. Y., Garnett, S., Ghei, M., Gibbons, N., Gilbert, H. W., Gillatt, D. A., Glackin, A., Godbole, H. C., Golash, A., Goodman, C. M., Gowardhan, B., Green, J. S. A., Griffiths, T. R. L., Gujral, S., Gunendran, T., Hagan, C. M., Haldar, N., Hanbury, D. C., Harney, J., Hasan, S. T., Hawkyard, S. J., Hayes, M. C., Haynes, M. D., Henderson, A., Hicks, J. A., Hindley, R. G., Hodgson, D. J., Hotston, M., Howell, G. P., Hrouda, D., Hughes, O. D. M., Hunter‐Campbell, P., Ilie, C., Issa, R., Jain, S., Jain, A., Janjua, K. S., Javle, P., Johnson, P., Johnson, M. I., Jones, A., Joshi, H., Joyce, A. D., Kanaga‐Sundaram, S., Karim, O. M. A., Keeley, F. X., Kelkar, A., Kelleher, J. P., Khan, A., Khattak, A. Q., Khoubehi, B., Kimuli, M., Kirollos, M. M., Kockelbergh, R. C., Kooiman, G., Koupparis, A., Kumar, P., Kynaston, H. G., Laniado, M. E., Larner, T., Latif, Z., Lau, M. W., le Roux, P. J., Leung, S., Leveckis, J., Lewis, G., Liston, T. G., Lockyer, C. R. W., Lodge, R. N., Luscombe, C. J., Lynch, M., Lynch, C., Lynn, N. N. K., MacDermott, J. P., Mackie, S., Madaan, S., Maddineni, S.B., Maheshkumar, P., Makar, A. A., Makunde, J. T., Manikandan, R., Mann, G. S., Mantle, M., Mark, I. R., Matanhelia, S. S., McCabe, J., McClinton, S., McFarlane, J. P., McInerney, P. D., McIntyre, I. G., McLarty, E., McLornan, M. E., McLoughlin, J., McNeill, S. A., Mehta, S., Mellon, J. K., Menezes, P., Mills, R. D., Mokete, M., Montague, R., Morton, A. L., Motiwala, H. G., Mulholland, C. K., Mumtaz, F. H., Munro, N., Myatt, A., Nair, M., Namasivayam, S., Napier‐Hemy, R. D., Nathan, S., Neilson, D., Nicol, D. L., Nuttall, M., OʼBrien, T. S., OʼKane, H. F., OʼRiordan, A., Oades, G., Oakley, N., Okeke, A. A., Olsburgh, J., Paez, E., Page, T., Parkin, J., Parys, B. T., Patel, P., Patel, N., Patel, B., Pathak, S., Patil, K., Paul, A. B., Payne, D., Peracha, A. M., Peters, J. L., Phillips, S. M. A., Phillips, J. T., Phipps, S., Pillai, M. K., Potter, J. M., Prescott, S., Rajan, T. N., Rajjayabun, P., Ramani, V. A. C., Rane, A., Ravi, R., Ravichandran, S., Riddick, A. C. P., Rimington, P. D., Rix, G. H., Rix, D., Robinson, L. Q., Rochester, M., Rogawski, K. M., Rogers, A. G., Rowe, E., Sahadevan, K., Samsudin, A., Sandhu, S., Sangar, V. K., Sells, H., Shackley, D. C., Shah, Z., Shaikh, N. N. A., Sharma, H., Sherwood, B., Singh, S., Singh, G., Smith, D. J., Solomon, L., Soomro, N. A., Srinivasan, V., Sriprasad, S. I., Stephenson, R. N., Stewart, A., Stubington, S. R., Subramonian, K., Sullivan, M. E., Taneja, S., Thilagarajah, R., Thomas, S. A., Thomas, D. J., Thomas, B., Thompson, A. C., Thurston, A.V., Turner, K. J., Umez‐Eronini, O. N., Upsdell, S. M., Vale, J. A., Varadaraj, H., Vesey, S. G., Viney, R., Vohra, A. K., Walton, T., Warburton, H. E., Waymont, B., Webster, J. J., Webster, G. M., Wedderburn, A., Wemyss‐Holden, G. D., Weston, R., Whittlestone, T., Wilkinson, S., Wilkinson, B., Williams, S., Wills, M. I., Wilson, J. R., Wilson, I. D., Woodhouse, C. R. J., Wright, M., Yates, D. R., and Young, J. G.

Published
2017
Full Text
View/download PDF

14. Sustainability of Light Metal Packaging: Pods, Flexible Films and more [Webinar]

Author

Institute of Materials, Minerals & Mining, Allan J., Hindley R., Ludlow-Palafox C., IOM3 Packaging Society, Institute of Materials, Minerals & Mining, Allan J., Hindley R., Ludlow-Palafox C., and IOM3 Packaging Society

Abstract

Recycling is part of the life cycle of light metals and integral to a low carbon strategy. This second webinar in the series on recyclability of light metals will focus on the manufacture and recycling of packaging, including pods, laminates and flexible foils., You'll hear about: Aluminium in packaging, form and function, recyclability and recycling, Presented by Jude Allan; Looking at the use of aluminium in all its forms from the beverage can, aluminium bottles, flexibles and coffee pods, why it's used and the functionality that it brings to the packaging and the challenges of actually recycling what is a 100% recyclable material. Podback, a pioneering approach to recover and recycle coffee pods, Presented by Rick Hindley; Executive Director, Rick Hindley, will introduce Podback, the new nationwide recycling service for coffee pods. You will hear how Podback works, how its putting EPR into action and results of the scheme so far. Plastic recycling in the world of light metals packaging, Presented by Carlos Ludlow-Palafox; Hang on! Wasn’t this webinar about metal packaging sustainability? Yes, but it turns out that the world is fixated on plastics and that is actually a threat to metals in packaging and the wonderful job that metals have in protecting food. Carlos will present an overview of what has been happening in the world of flexible packaging in the context of the “war on plastics”, he will introduce the Enval process as one plastic recycling process that also recovers the metal in composite packaging. The discussion will feature: Novel recycling methodologies; Recycling of packaging which is employed in high volumes; Recycling systems known to be carried out by a single company., Recycling is part of the life cycle of light metals and integral to a low carbon strategy. This second webinar in the series on recyclability of light metals will focus on the manufacture and recycling of packaging, including pods, laminates and flexible foils., You'll hear about: Aluminium in packaging, form and function, recyclability and recycling, Presented by Jude Allan; Looking at the use of aluminium in all its forms from the beverage can, aluminium bottles, flexibles and coffee pods, why it's used and the functionality that it brings to the packaging and the challenges of actually recycling what is a 100% recyclable material. Podback, a pioneering approach to recover and recycle coffee pods, Presented by Rick Hindley; Executive Director, Rick Hindley, will introduce Podback, the new nationwide recycling service for coffee pods. You will hear how Podback works, how its putting EPR into action and results of the scheme so far. Plastic recycling in the world of light metals packaging, Presented by Carlos Ludlow-Palafox; Hang on! Wasn’t this webinar about metal packaging sustainability? Yes, but it turns out that the world is fixated on plastics and that is actually a threat to metals in packaging and the wonderful job that metals have in protecting food. Carlos will present an overview of what has been happening in the world of flexible packaging in the context of the “war on plastics”, he will introduce the Enval process as one plastic recycling process that also recovers the metal in composite packaging. The discussion will feature: Novel recycling methodologies; Recycling of packaging which is employed in high volumes; Recycling systems known to be carried out by a single company.

Published
2021

16. Cancer control outcomes following focal therapy using HIFU in 1,829 men with non-metastatic prostate cancer treated over 15 years

Author

Reddy, D.T., primary, Peters, M., additional, Shah, T., additional, Van Son, M., additional, Huber, P., additional, Lomas, D., additional, Rakauskas, A., additional, Miah, S., additional, Guillaumier, S., additional, Dudderidge, T., additional, Hindley, R., additional, Emara, A., additional, Nigam, R., additional, Valerio, M., additional, Afzal, N., additional, Lewi, H., additional, Orczyk, C., additional, Ogden, C., additional, Persad, R., additional, Virdi, J., additional, Moore, C., additional, Arya, M., additional, Winkler, M., additional, Emberton, M., additional, and Ahmed, H., additional

Published
2021
Full Text
View/download PDF

18. Focal ablative salvage therapy for radio-recurrent prostate cancer: 6 year oncological and safety outcomes

Author

Reddy, D.T., primary, Peters, M., additional, Shah, T., additional, Van Son, M., additional, Hosking-Jervis, F., additional, Miah, S., additional, Bertoncelli Tanaka, M., additional, Eldred-Evans, D., additional, Guillaumier, S., additional, Huber, P., additional, Lomas, D., additional, Rakauskas, A., additional, Dudderidge, T., additional, Mccracken, S., additional, Hindley, R., additional, Emara, A., additional, Nigam, R., additional, Persad, R., additional, Virdi, J., additional, Moore, C., additional, Orczyk, C., additional, Emberton, M., additional, Arya, M., additional, Winkler, M., additional, and Ahmed, H., additional

Published
2021
Full Text
View/download PDF

19. MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial

Author

Shah, T.T., primary, Kanthabalan, A., additional, Pavlou, M., additional, Adeleke, S., additional, Giganti, F., additional, Brew-Graves, C., additional, Williams, N.R, additional, Haroon, A., additional, Sidhu, H., additional, Freeman, A., additional, Orczyk, C., additional, Nikapota, A., additional, Dudderidge, T., additional, Hindley, R., additional, Virdi, J., additional, Arya, M., additional, Mitra, A., additional, Payne, H., additional, Bomanji, J., additional, Winkler, M., additional, Horan, G., additional, Moore, C., additional, Emberton, M., additional, Punwani, S., additional, and Ahmed, H.U, additional

Published
2021
Full Text
View/download PDF

20. MRI index lesions in the cancerous prostate: How do they differ from false positive phenotypes? Lessons from the PROMIS study

Author

Stavrinides, V., primary, Norris, J., additional, Bott, S., additional, Brown, L., additional, Burns-Cox, N., additional, Dudderidge, T., additional, El-Shater Bosaily, A., additional, Frangou, E., additional, Freeman, A., additional, Ghei, M., additional, Henderson, A., additional, Hindley, R., additional, Kaplan, R., additional, Kirkham, A., additional, Oldroyd, R., additional, Parker, C., additional, Persad, R., additional, Punwani, S., additional, Rosario, D., additional, Shergill, I., additional, Carmona, L., additional, Winkler, M., additional, Whitaker, H., additional, Ahmed, H., additional, and Emberton, M., additional

Published
2020
Full Text
View/download PDF

25. Comparison of TRUS-Biopsy to transperineal template mapping biopsies stratified by multi-parametric MRI score within the PROMIS trial

Author

Lovegrove, C, Miah, S, El-Shater Bosaily, A, Bott, S, Brown, L, Burns-Cox, N, Dudderidge, T, Freeman, A, Henderson, A, Hindley, R, Kaplan, R, Kirkham, A, Oldroyd, R, Parker, C, Persad, R, Punwani, S, Rosario, D, Shergill, I, Winkler, M, Emberton, M, Ahmed, HU, Wellcome Trust, University College London Hospitals Charity, Imperial Health Charity, and Medical Research Council (MRC)

Subjects
Image-Guided Biopsy, Male, transrectal, prostate, Prostatic Neoplasms, template, 1103 Clinical Sciences, ultrasonography, Urology & Nephrology, urologic and male genital diseases, Magnetic Resonance Imaging, Sensitivity and Specificity, predictive value of tests, Humans, biopsy, Prospective Studies, Neoplasm Grading, Ultrasonography, Interventional, MRI
Abstract

INTRODUCTION: We evaluated performance of transrectal ultrasound-guided systematic (TRUS) biopsy compared to transperineal template mapping (TPM) with a 5mm sampling frame, stratified by MP-MRI Likert score within the PROMIS study. METHODS: Biopsy-naïve men due prostate biopsy for elevated PSA and/or abnormal digital rectal examination underwent MP-MRI, TPM and TRUS biopsies, conducted and reported blind to other test results. Clinically significant prostate cancer (csPCa) was primarily defined as Gleason >/=4+3 or maximum cancer core length (MCCL) >/=6mm of any grade, and secondarily Gleason >/=3+4 or MCCL >/=4mm of any grade. RESULTS: In 41 months, 740 men at 11 centres were recruited; 576 underwent all three tests. Of 150 with MRI score 1-2, 8 (5.1%) had any Gleason >/=3+4 disease on TRUS-biopsy. In 75 where TRUS-biopsy showed Gleason 3+3 of any MCCL, 61/75 (81%) had Gleason 3+4, 8/75 (11%) Gleason 4+3 and 0/75 (0%) Gleason >/=4+5. For definition1 csPCa, TRUS-biopsy sensitivity remained stable and low across MP-MRI Likert scores (35%-52%). For definition2 csPCa and any cancer, sensitivity increased with higher MP-MRI score. Negative predictive value varied due to varying disease prevalence but for all cancer thresholds declined with increasing MP-MRI score. CONCLUSIONS: TRUS-biopsy in the setting of MP-MRI Likert scores 1-2 finds Gleason 3+4 disease in only 1 in 20 men. Further, for any csPCa definition, TRUS-biopsy had poor sensitivity and variable but low NPV across MP-MRI scores. Men undergoing TRUS-biopsy without targeting in the setting of MP-MRI score 3 to 5 should be advised to undergo a repeat (targeted) biopsy.

Published
2019

32. Medium term oncological outcomes in a large cohort of men treated with either focal- or hemi-ablation with HIFU for primary localized prostate cancer

Author

Nocera, L., primary, Stabile, A., additional, Orkzyc, C., additional, Hosking-Jervis, F., additional, Giganti, F., additional, Arya, M., additional, Hindley, R., additional, Dickinson, L., additional, Allen, C., additional, Punwani, S., additional, Jameson, C., additional, Freeman, A., additional, McCartan, N., additional, Montorsi, F., additional, Briganti, A., additional, Ahmed, H., additional, Emberton, M., additional, and Moore, C., additional

Published
2019
Full Text
View/download PDF

33. Medium term oncological outcomes in a large cohort of men treated with either focal- or hemi-ablation with HIFU for primary localized prostate cancer

Author

Stabile, A., primary, Orczyk, C., additional, Hosking-Jervis, F., additional, Giganti, F., additional, Arya, M., additional, Hindley, R., additional, Dickinson, L., additional, Allen, C., additional, Punwani, S., additional, Jameson, C., additional, Freeman, A., additional, McCartan, N., additional, Montorsi, F., additional, Briganti, A., additional, Ahmed, H., additional, Emberton, M., additional, and Moore, C., additional

Published
2019
Full Text
View/download PDF

36. Focal Salvage HIFU in radiorecurrent prostate cancer

Author

Kanthabalan, A, Peters, M, Van Vulpen, M, McCartan, N, Hindley, R G, Emara, A, Moore, M C, Arya, M, Emberton, M, and Ahmed, H U

Subjects
focal salvage HIFU, radiorecurrent prostate cancer, Journal Article
Abstract

OBJECTIVE: To assess short to medium term cancer control rates and side effects of focal salvage High Intensity Focused Ultrasound (HIFU). MATERIALS AND METHODS: A retrospective registry analysis identified 150 men who underwent focal salvage HIFU (Sonablate 500) (November 2006-August 2015). Metastatic disease was excluded using the nodal assessment on the pelvic MRI, a radioisotope bone scan and PET imaging (choline-FDG-PET or Choline PET-CT). In our current clinical practice, metastatic disease must be ruled out by both Choline PET and bone scan. Localisation of cancer was by multi-parametric prostate MRI (T2W, diffusion-weighting, dynamic contrast enhancement) with systematic or template prostate mapping biopsies. Primary outcome was a composite failure incorporating biochemical failure (BF) and/or positive localised or distant imaging and/or positive biopsy and/or systemic therapy and/or metastases/prostate cancer specific death. Secondary outcome was BF using the Phoenix-ASTRO definition (nadir+2ng/ml). We used Kaplan-Meier analysis and Cox-proportional hazards regression to quantify the effect of the determinants on the endpoints. RESULTS: Mean age at focal salvage therapy was 69.8 years (SD 6.1) and median PSA pre-focal salvage treatment was 5.5 ng/ml [IQR 3.6-7.9). Median follow-up was 35 months (IQR 22-52). Patients were classified as low 2.7% (4/150), intermediate 39.3% (59/150) and high-risk disease 41.3% (62/150) according to D'Amico classification, prior to focal salvage HIFU. Composite failure occurred in 61% (91/150) and BF occurred in 51.3% (77/150). The Kaplan-Meier composite endpoint free survival (CEFS) at 3 years was 40% (95% CI 31-50) for the entire group. Kaplan-Meier estimates of CEFS were 100%, 49% and 24% at 3 years in low, intermediate and high D'Amico risk groups pre-salvage, respectively. The Kaplan-Meier biochemical disease free survival (BDFS) at 3 years was 48% (95% CI 39-59) for the entire group. Kaplan-Meier estimates of BDFS was 100%, 61% and 32% at 3 years in low, intermediate and high D'Amico risk groups pre-salvage, respectively. Complications included urine infection (11.3%; 17/150), bladder neck stricture (8%; 12/150), recto-urethral fistula after 1 HIFU procedure (2%; 3/150) and osteitis pubis (0.7%; 1/150). CONCLUSION: Focal salvage HIFU confers a relatively low complication and side-effect rate. Composite endpoint free survival and biochemical control in the short to medium term is reasonable, especially in this relatively high risk cohort but still on the lower end compared to current whole gland salvage therapies. Focal salvage therapy may offer disease control in high risk men whilst minimising additional treatment morbidities. This article is protected by copyright. All rights reserved.

Published
2017

38. Focal Salvage HIFU in radiorecurrent prostate cancer

Author

Onderzoek Radiotherapie, Cancer, Radiotherapie, Kanthabalan, A, Peters, M, Van Vulpen, M, McCartan, N, Hindley, R G, Emara, A, Moore, M C, Arya, M, Emberton, M, Ahmed, H U, Onderzoek Radiotherapie, Cancer, Radiotherapie, Kanthabalan, A, Peters, M, Van Vulpen, M, McCartan, N, Hindley, R G, Emara, A, Moore, M C, Arya, M, Emberton, M, and Ahmed, H U

Published
2017

39. The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial

Author

El-Shater Bosaily, A, Valerio, M, Hu, Y, Freeman, A, Jameson, C, Brown, L, Kaplan, R, Hindley, R G, Barratt, D, Emberton, M, and Ahmed, H U

Subjects
Image-Guided Biopsy, Male, GLEASON SCORE, Aged, Aged, 80 and over, Biomarkers, Tumor, Humans, Imaging, Three-Dimensional, Magnetic Resonance Imaging/methods, Middle Aged, Neoplasm Grading, Prostatic Neoplasms/diagnostic imaging, Prostatic Neoplasms/pathology, Tumor Burden, ACCURACY, urologic and male genital diseases, COMPUTER-SIMULATION, MAPPING BIOPSY, Science & Technology, RADICAL PROSTATECTOMY, Prostatic Neoplasms, MEN, Urology & Nephrology, RANDOMIZED CONTROLLED-TRIAL, Magnetic Resonance Imaging, AGGRESSIVENESS, Oncology, INSIGNIFICANT PROSTATE-CANCER, Original Article, Corrigendum, Life Sciences & Biomedicine, 1112 Oncology And Carcinogenesis, MRI
Abstract

Objectives: The rationale for directing targeted biopsy towards the centre of lesions has been questioned in light of prostate cancer grade heterogeneity. In this study, we assess the assumption that the maximum cancer Gleason grade (Gleason grade hotspot) lies within the maximum dimension (volume hotspot) of a prostate cancer lesion. Methods: 3-D histopathological models were reconstructed using the outputs of the 5-mm transperineal mapping (TPM) biopsies used as the reference test in the pilot phase of Prostate Mri Imaging Study (PROMIS), a paired validating cohort study investigating the performance of multi-parametric magnetic resonance imaging (MRI) against transrectal ultrasound (TRUS) biopsies. The prostate was fully sampled with 5 mm intervals; each core was separately labelled, inked and orientated in space to register 3-D cancer lesions location. The data from the histopathology results were used to create a 3-D interpolated reconstruction of each lesion and identify the spatial coordinates of the largest dimension (volume hot spot) and highest Gleason grade (Gleason grade hotspot) and assess their concordance. Results: Ninety-four men, with median age 62 years (interquartile range, IQR= 58–68) and median PSA 6.5 ng ml−1 (4.6–8.8), had a median of 80 (I69–89) cores each with a median of 4.5 positive cores (0–12). In the primary analysis, the prevalence of homogeneous lesions was 148 (76%; 95% confidence interval (CI) ±6.0%). In all, 184 (94±3.2%) lesions showed concordant hotspots and 11/47 (23±12.1%) of heterogeneous lesions showed discordant hotspots. The median 3-D distance between discordant hotspots was 12.8 mm (9.9–15.5). These figures remained stable on secondary analyses using alternative reconstructive assumptions. Limitations include a certain degree of error within reconstructed models. Conclusions: Guiding one biopsy needle to the maximum cancer diameter would lead to correct Gleason grade attribution in 94% of all lesions and 79% of heterogeneous ones if a true hit was obtained. Further correlation of histological lesions, their MRI appearance and the detectability of these hotspots on MRI will be undertaken once PROMIS results are released.

Published
2016

41. A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study

Author

Leslie, T., primary, Elliott, D., additional, Le Conte, S., additional, Brewster, S., additional, Sooriakumaran, P., additional, Bryant, R., additional, Dudderidge, T., additional, Rosario, D., additional, Catto, J., additional, Hindley, R., additional, Emberton, M., additional, Ahmed, H., additional, Donovan, J., additional, and Hamdy, F., additional

Published
2017
Full Text
View/download PDF

45. 841 Medium term outcomes following focal HIFU for the treatment of non-metastatic prostate cancer: A UK registry analysis of 625 cases

Author

Guillaumier, S., primary, Hamid, S., additional, Charman, S., additional, Van Der Meulen, J., additional, McCartan, N., additional, Shah, K., additional, Hindley, R., additional, Nigam, R., additional, Dudderidge, T., additional, Afzal, N., additional, Cornaby, A., additional, Lewi, H., additional, Persad, R., additional, Moore, C., additional, Virdi, J., additional, Arya, M., additional, Emberton, M., additional, and Ahmed, H.U., additional

Published
2016
Full Text
View/download PDF

46. 1088 Effects of 5α-reductase inhibition on benign prostatic hyperplasia treated by photoselective vaporization prostatectomy with the 180 Watt GreenLight XPS laser system: Results from the GOLIATH population

Author

Brassetti, A., primary, Bachmann, A., additional, Tubaro, A., additional, Barber, N., additional, D'Ancona, F., additional, Muir, G., additional, Witzsch, U., additional, Grimm, M.O., additional, Benejam, J., additional, Stolzenburg, J.U., additional, Riddick, A., additional, Pahernik, S., additional, Roelink, J., additional, Ameye, F., additional, Saussine, C., additional, Bruyere, F., additional, Loidl, W., additional, Larner, T., additional, Gogoi, N., additional, Hindley, R., additional, Muschter, R., additional, Thorpe, A., additional, Shrotri, N., additional, Graham, S., additional, Hamann, M., additional, Miller, K., additional, Schostak, M., additional, Capitan, C., additional, Knispel, H., additional, and Thomas, A., additional

Published
2016
Full Text
View/download PDF

47. 572 Functional results of a prospective randomized controlled study comparing GreenLight XPS to TURP demonstrate durable efficacy and safety at 24-months (GOLIATH)

Author

Thomas, J.A., primary, Tubaro, A., additional, Barber, N., additional, D'Ancona, F., additional, Muir, G., additional, Witzsch, U., additional, Grimm, M-O., additional, Benejam, J., additional, Stolzenburg, J-U., additional, Riddick, A., additional, Pahernik, S., additional, Roelink, J., additional, Ameye, F., additional, Saussine, C., additional, Bruyere, F., additional, Loidl, W., additional, Larner, T., additional, Gogoi, N., additional, Hindley, R., additional, Muschter, R., additional, Thorpe, A., additional, Shrotri, N., additional, Graham, S., additional, Hamann, M., additional, Miller, K., additional, Schostak, M., additional, Capitan, C., additional, Knispel, H., additional, and Bachmann, A., additional

Published
2015
Full Text
View/download PDF

50. 128 Prospective randomized controlled trial comparing GreenLight (GL) 180-W XPS PVP and transurethral resection of the prostate (the Goliath Study): Patient questionnaires and one year follow-up

Author

Bachmann, A., primary, Tubaro, A., additional, Barber, N., additional, D'Ancona, F., additional, Gordon, M., additional, Witzsch, U., additional, Grimm, M-O., additional, Benejam, J., additional, Stolzenburg, J-U., additional, Riddick, A., additional, Pahernik, S., additional, Roelink, J., additional, Ameye, F., additional, Saussine, C., additional, Bruyere, F., additional, Loidl, W., additional, Larner, T., additional, Gogoi, N., additional, Hindley, R., additional, Muschter, R., additional, Thorpe, A., additional, Shrotri, N., additional, Graham, S., additional, Hamann, M., additional, Miller, K., additional, Schostak, M., additional, Capitan, C., additional, Knispel, H., additional, and Thomas, A., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results